Avanos Medical

Traded on the St. Petersburg Stock Exchange
Avanos Medical, Inc. is a medical technology company focused on delivering clinical medical device solutions. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
Avanos Medical stock price chart
vol.
change
P/E adj.
Net profit (adj.)
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Avanos Medical balance sheet

Report period2018 2019 2020 2021 20222023
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Avanos Medical cash flows

Report period2018 2019 2020 2021 20222023
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
Adjusted Earnings
EBITDA
Adjusted EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS
Adjusted EPS

Avanos Medical multipliers

Report period2018 2019 2020 2021 20222023
P/E
P/E adj.
E/P
E adj./P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
Net Debt/EBITDA adj.
EV/EBITDA
EV/EBITDA adj.

Avanos Medical profitability

Report period2018 2019 2020 2021 20222023
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Avanos Medical assets
Avanos Medical cash flows

Avanos Medical shares

TickerNameTypeNominal valueISINPrice
AVNS:USAvanos Medical, Inc.Common share-US05350V1061$18.71
Avanos Medical news
04.05.2022
Avanos Medical's GAAP net income for 3 months of 2022 was $5.8 million, compared to a loss of $7.6 million in the previous year. Revenue increased 9.2% to $197.4 million from $180.7 million a year earlier.
23.02.2022
Net income of Avanos Medical under GAAP for 2021 was $5.2 million, compared to a loss of $27.2 million in the previous year. Revenue increased 4.2% to $744.6 million from $714.8 million a year earlier.
14.12.2021
Avanos Medical is acquiring OrthogenRx for $160 million. The company is developing drugs for pain management in osteoarthritis of the knee. Avanos Medical will pay $130 million and another $30 million upon reaching certain milestones in the development of its GenVisc 850 and TriVisc drugs. The deal is scheduled to close in Q1 2022.
02.11.2021
Avanos Medical's GAAP loss for 9M 2021 was $4.8 million, against a profit of $20 million in the previous year. Revenue increased 4% to $551.2 million from $529.8 million a year earlier.
General information
Company nameAvanos Medical
SectorHealth Care / Health Care Equipment & Services / Health Care Equipment & Supplies / Health Care Supplies
Business address5405 WINDWARD PARKWAY ALPHARETTA GA 30004 678-425-9273
Mailing address5405 WINDWARD PARKWAY ALPHARETTA GA 30004
Websitewww.avanos.com